OXiGENE Appoints Bill Schwieterman, M.D., as President and Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil rebounds, Middle East tensions simmer
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
OXiGENE (OXGN) Announces Appointment of New CEO
May 12, 2015 4:00 PM EDTOXiGENE (NASDAQ: OXGN) announced the appointment of a new President and Chief Executive Officer, Bill Schwieterman, M.D. The company's current CEO, Dai Chaplin, Ph.D., will become Chief Scientific Officer. Both Drs. Schwieterman and Chaplin will continue to serve on OXiGENE's board of directors.
Dr. Schwieterman is an experienced biotechnology executive with a deep background in clinical development and regulatory matters. From 2009 to 2014, he was Chief Medical Officer of Chelsea Therapeutics, Inc., where he led the company's clinical... More
